Management of Hypoglycemia in CKD Stage 5 Patients on Insulin and DPP-4 Inhibitors

Insulin Dose Adjustment in CKD Stage 5

Total daily insulin dose should be reduced by 50% in patients with type 2 diabetes and CKD stage 5, as recommended by the American Diabetes Association 1
Decreased renal insulin clearance, impaired renal gluconeogenesis, and prolonged insulin half-life contribute to the need for insulin dose reduction in CKD stage 5, according to the National Kidney Foundation 2
The American College of Endocrinology recommends starting with a low dose of Lantus, such as 5 units once daily, and titrating conservatively upward only if needed to avoid hypoglycemia 1, 3

No dose adjustment is required for linagliptin regardless of kidney function, including CKD stage 5, as stated by the American Association of Clinical Endocrinologists 1, 3
Linagliptin has a low risk of hypoglycemia when used alone, but the risk increases when combined with insulin, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 4

The American Diabetes Association recommends targeting an HbA1c of 7-8% in patients with advanced CKD and high hypoglycemia risk 5
HbA1c is less reliable in CKD stage 5 due to anemia, erythropoietin use, and altered red blood cell lifespan, as noted by the National Institute of Diabetes and Digestive and Kidney Diseases 5
The European Association for the Study of Diabetes recommends increasing the frequency of home blood glucose monitoring to detect hypoglycemia patterns in patients with CKD stage 5 5

The American College of Endocrinology recommends immediately reducing Lantus to 5 units once daily and monitoring fasting blood glucose daily for 1-2 weeks 1
If fasting glucose remains high, the dose can be increased by 1-2 units every 3-5 days, but never by more than 10-20% at a time, as advised by the American Journal of Kidney Diseases 3, 7

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines state that hypoglycemia risk is 5-fold higher in patients with advanced CKD on insulin 2
The American Association of Clinical Endocrinologists recommends reducing basal insulin dose by 25% on pre-dialysis days if the patient is on hemodialysis 1
Hypoglycemia-related hospitalizations before dialysis initiation are strongly associated with higher mortality after transition to dialysis, according to the National Kidney Foundation 5

The American Diabetes Association recommends adding a GLP-1 receptor agonist, such as dulaglutide or semaglutide, if glycemic control remains inadequate despite insulin optimization, as they require no dose adjustment and have low hypoglycemia risk 3, 4
The European Association for the Study of Diabetes suggests considering adding an SGLT2 inhibitor if eGFR permits, as it can be continued even if eGFR falls below 20 ml/min/1.73m² once initiated 3, 8

The American College of Endocrinology recommends educating patients on hypoglycemia symptoms and treatment, as hypoglycemia awareness may be impaired in CKD 2, 5
The National Kidney Foundation advises temporarily holding insulin or reducing the dose by an additional 20-30% during acute illness 7
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend monitoring for signs of volume depletion if adding an SGLT2 inhibitor 3
The American Association of Clinical Endocrinologists suggests reassessing insulin requirements every 3-6 months as kidney function may continue to decline 3, 6